Episodios

  • HCPLive 5 Stories in Under 5: Week of 06/22

    HCPLive 5 Stories in Under 5: Week of 06/22
    Jun 30 2025
    Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!

    Interested in a more traditional, text rundown? Check out the HCPFive!

    Top 5 Healthcare Headlines for June 16-22, 2025:
    Pemvidutide Shows Significant MASH Effects, Weight Loss at 24 Weeks in Phase 2b IMPACT Trial
    Topline phase 2b data show pemvidutide achieved significant rates of MASH resolution and fibrosis improvement alongside meaningful weight loss at 24 weeks, positioning it as a promising candidate for metabolic liver disease treatment.

    FDA Approves Belimumab (Benlysta) Autoinjector for Pediatric Lupus Nephritis
    The FDA approved a belimumab autoinjector for at-home subcutaneous use in children as young as five with active lupus nephritis, providing the first approved biologic self-injection option for pediatric SLE and LN.

    Phase 3 Trial Results Announced for Sotatercept-csrk in Pulmonary Arterial Hypertension
    Positive phase 3 results show sotatercept-csrk added to background therapy reduced time to clinical worsening events in adults with PAH, supporting its potential as an effective treatment for this high-risk population.

    Compass Pathways’ COMP360 Psilocybin Shows Benefit in Phase 3 TRD Trial
    COMP360 psilocybin demonstrated a significant reduction in depression symptom severity in treatment-resistant depression, meeting the primary endpoint in a pivotal phase 3 trial.

    Once-Monthly Obesity Drug, MariTide, Achieves Weight Loss Up to 16% at 1 Year
    Phase 2 data indicate once-monthly MariTide induces substantial weight loss of up to 16% over one year, with additional improvements in glycemic control, highlighting its promise for obesity and type 2 diabetes management.
    Más Menos
    5 m
  • Medical Ethics Unpacked: Shifting Vaccine Regulation and Policy, with Jason Schwartz, PhD

    Medical Ethics Unpacked: Shifting Vaccine Regulation and Policy, with Jason Schwartz, PhD
    Jun 18 2025
    In this episode of Medical Ethics Unpacked, hosts Dominic Sisti and Steve Levine welcome Jason Schwartz, PhD, associate professor at the Yale School of Public Health, for a discussion on vaccine ethics, public health infrastructure, and the challenges of maintaining trust in immunization programs.

    Together, they explore how the COVID-19 pandemic reshaped public attitudes toward vaccines, while also underscoring long-standing tensions between individual autonomy and collective responsibility. Schwartz, whose work focuses on vaccine policy and history, offers perspective on the systems and institutions, such as the CDC's Advisory Committee on Immunization Practices (ACIP), helping to translate scientific evidence into public health recommendations.

    This episode comes at a time when ACIP is once again in the headlines as HHS Secretary Robert F. Kennedy Jr. recently replaced all 17 members with a new slate of individuals, citing concerns about groupthink and conflicts of interest. The move has generated widespread commentary about the role and value of such expert advisory bodies in shaping public health decisions, especially in the face of growing skepticism and political scrutiny.

    Ethical questions about equity, communication, and responsibility are threaded throughout the discussion. The hosts and Schwartz reflect on what it means to make fair vaccine recommendations in the context of incomplete data, and how institutions can maintain public trust amid scientific uncertainty. They also discuss how the infrastructure behind public health decisions—committees, advisory boards, and interagency coordination—can either strengthen or undermine confidence depending on how they function and how well they are understood.

    Chapters
    00:00 – Introduction and Vaccine Policy in Crisis
    03:00 – The Long History and New Politics of Vaccine Skepticism
    09:30 – Erosion of Public Health Infrastructure and Expert Advisory Systems
    14:50 – Why Vaccines Became a Political Flashpoint
    19:10 – Clinician Ethics and the Vaccine-Hesitant Patient
    32:00 – Data, Misinformation, and the Future of Vaccine Trust


    References:

    Stone W. RFK Jr. names new slate of vaccine advisers after purging CDC panel. NPR. Published June 11, 2025. Accessed June 17, 2025. https://www.npr.org/sections/shots-health-news/2025/06/11/nx-s1-5430870/cdc-vaccine-experts-rfk-jr

    Asturias EJ, Brewer NT, Brooks O, et al. Advisory Committee on Immunization Practices at a Crossroads. JAMA. Published online June 16, 2025. doi:10.1001/jama.2025.10776
    Más Menos
    46 m
  • HCPLive 5 Stories in Under 5: Week of 06/08

    HCPLive 5 Stories in Under 5: Week of 06/08
    Jun 14 2025
    Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!

    Interested in a more traditional, text rundown? Check out the HCPFive!

    Top 5 Healthcare Headlines for June 2-8, 2025.

    FDA Approves Clesrovimab RSV Immunization for Newborns and Infants
    The FDA has approved clesrovimab (Enflonsia) for the prevention of RSV lower respiratory tract disease in infants, based on results from two late-stage clinical trials evaluating its safety and efficacy.

    FDA Approves Glecaprevir/Pibrentasvir (Mavyret) Label Expansion for Acute HCV
    The FDA has expanded the indication for glecaprevir/pibrentasvir to include treatment of acute hepatitis C virus infection in adults and children aged three years and older, regardless of cirrhosis status.

    FDA Approves Prednisolone Acetate Ophthalmic Suspension for Ocular Inflammation
    Prednisolone acetate ophthalmic suspension 1% has received FDA approval as a topical steroid treatment for steroid-responsive ocular inflammation, with product launch expected later in 2025.

    FDA Grants Fast Track Designation to Mavorixafor for Chronic Neutropenia
    The FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia, supporting its ongoing phase 3 evaluation following earlier approval for WHIM syndrome.

    Iptacopan (Fabhalta) Hits Primary Endpoint in Phase 3 APPULSE-PNH Trial
    Phase 3 data show iptacopan (Fabhalta) is effective and well-tolerated in adults with PNH who transitioned from anti-C5 therapy, achieving key hematologic outcomes and symptomatic improvement.
    Más Menos
    5 m
  • Liver Lineup: Advances in MASH, PSC, and PBC Care at EASL 2025

    Liver Lineup: Advances in MASH, PSC, and PBC Care at EASL 2025
    Jun 11 2025
    In this episode of Liver Lineup: Updates & Unfiltered Insights, hosts Kimberly Brown, MD, a professor of Medicine at Michigan State University and Wayne State University, associate medical director of the Henry Ford Hospital Transplant Institute, and medical director of Transplant Outreach Services at Henry Ford Hospital, and Nancy Reau, MD, a professor of internal medicine, the Richard B. Capps Chair of Hepatology, associate director of solid organ transplantation, and the section chief of hepatology at Rush University Medical Center, continue their discussion on notable abstracts presented at the 2025 European Association for the Study of the Liver (EASL) Congress.

    If you haven't already, be sure to check out part 1 here!

    Key Episode Timestamps

    0:00:00 LITMUS Study

    0:05:47 Norursodeoxycholic Acid in PSC

    0:10:12 GLOBE Score for PBC

    0:15:11 Conclusion

    Arbutus, and VIR. Relevant disclosures for Brown include Mallinckrodt Pharmaceuticals, Gilead, Salix, Intercept, Ipsen, and Madrigal.
    Más Menos
    15 m
  • Liver Lineup: New MASLD and PBC Agents, PEth Testing, and HBV Functional Cure at EASL 2025

    Liver Lineup: New MASLD and PBC Agents, PEth Testing, and HBV Functional Cure at EASL 2025
    Jun 11 2025
    In this episode of Liver Lineup: Updates & Unfiltered Insights, hosts Kimberly Brown, MD, a professor of Medicine at Michigan State University and Wayne State University, associate medical director of the Henry Ford Hospital Transplant Institute, and medical director of Transplant Outreach Services at Henry Ford Hospital, and Nancy Reau, MD, a professor of internal medicine, the Richard B. Capps Chair of Hepatology, associate director of solid organ transplantation, and the section chief of hepatology at Rush University Medical Center, highlight 4 key abstracts presented at the 2025 European Association for the Study of the Liver (EASL) Congress.

    Key Episode Timestamps

    00:00:01 Introduction

    00:00:45 Efimosfermin Alfa in MASH

    00:05:56 PEth Testing

    00:13:19 RETRACT-B

    00:20:44 Linerixibat in PBC

    Relevant Disclosures for Reau include AbbVie, Gilead, Salix, Arbutus, and VIR. Relevant disclosures for Brown include Mallinckrodt Pharmaceuticals, Gilead, Salix, Intercept, Ipsen, and Madrigal.
    Más Menos
    24 m
  • HCPLive 5 Stories in Under 5: Week of 05/18

    HCPLive 5 Stories in Under 5: Week of 05/18
    May 26 2025
    Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!

    Interested in a more traditional, text rundown? Check out the HCPFive!

    Top 5 Healthcare Headlines for May 12-18, 2025.

    FDA Approves Once-Daily Roflumilast (ZORYVE) Foam 0.3% for Scalp and Body Psoriasis

    The FDA approved once-daily roflumilast (Zoryve) foam 0.3% for treating plaque psoriasis on the scalp and body in patients aged 12 and older. This marks the fifth overall indication for roflumilast, adding to its existing approvals in psoriasis and atopic dermatitis.

    FDA Warns About Rare, Severe Itching After Stopping Cetirizine or Levocetirizine

    The FDA issued a warning about severe pruritus that can occur after stopping long-term cetirizine or levocetirizine use. Manufacturers will be required to add a label warning noting that symptoms may improve if the medications are restarted.

    FDA Approves Susvimo for Treatment of Diabetic Retinopathy

    The FDA approved Genentech’s Susvimo, a ranibizumab delivery system, as the first continuous refillable treatment for diabetic retinopathy. Susvimo offers sustained vision maintenance with refills needed only once every nine months.

    Olezarsen Cuts Triglyceride Levels at 6 Months in Essence Study

    The Essence study showed olezarsen significantly reduced triglyceride levels in patients with moderate hypertriglyceridemia at ASCVD risk. Monthly doses achieved about 60% reductions, with most patients reaching normal triglyceride levels after six months.

    Ruxoprubart Shows Efficacy for PNH in Interim Phase 2 Trial Results

    Interim Phase 2 results showed ruxoprubart met all primary efficacy endpoints in adults with paroxysmal nocturnal hemoglobinuria. The therapy led to transfusion avoidance, improved hemoglobin, reduced LDH, and increased PNH clone size at 12 weeks.
    Más Menos
    4 m
  • HCPLive 5 Stories in Under 5: Week of 05/11

    HCPLive 5 Stories in Under 5: Week of 05/11
    May 17 2025
    Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!

    Interested in a more traditional, text rundown? Check out the HCPFive!

    Top 5 Healthcare Headlines for May 5- 11, 2025:

    FDA Accepts Sparsentan (Filspari) sNDA for Focal Segmental Glomerulosclerosis

    The FDA will review Travere Therapeutics’ application for full approval of sparsentan in FSGS, with an advisory committee meeting planned ahead of a January 2026 decision.

    FDA Accepts BioCryst’s NDA for Berotralstat Oral Granules in Children With HAE

    The FDA is evaluating berotralstat oral granules for pediatric hereditary angioedema, which could become the first oral preventive therapy for children under 12.

    SURMOUNT-5: Tirzepatide (Zepbound) Proves Benefit over Semaglutide (Wegovy) for Obesity

    Tirzepatide demonstrated superior weight loss outcomes compared with semaglutide in the SURMOUNT-5 trial for patients with obesity.

    Crinecerfont Reduces Steroid Use for Pediatric CAH in Phase 3 Analysis

    Crinecerfont lowered steroid requirements while maintaining hormone control in children with classic congenital adrenal hyperplasia, regardless of baseline characteristics.

    Type 1 Diabetes Diagnosed in Adulthood Heightens Cardiovascular Risk

    Adults diagnosed with type 1 diabetes face increased cardiovascular and all-cause mortality risks, regardless of age at diagnosis, according to long-term national data.
    Más Menos
    4 m
  • HCPLive Under 5 Audio Recap: Week of 05/04

    HCPLive Under 5 Audio Recap: Week of 05/04
    May 11 2025
    Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!

    Interested in a more traditional, text rundown? Check out the HCPFive!

    Top 5 Healthcare Headlines for April 28-May 4, 2025:

    Obicetrapib Achieves Robust LDL-C Reductions in Phase 3 ASCVD Trials

    Obicetrapib significantly reduced LDL-C as monotherapy and in combination with ezetimibe in ASCVD patients inadequately controlled by statins, according to Phase 3 data presented at EAS 2025.

    MAR001 Cuts Remnant Cholesterol, Triglycerides by 50% in Phase 2a Trial

    MAR001, a novel ANGPTL4-targeting monoclonal antibody, reduced remnant cholesterol and triglycerides by over 50% in high-risk patients, suggesting a promising new cardiovascular intervention strategy.

    Oral Zervimesine Reduces Geographic Atrophy Lesion Growth in Phase 2 Trial

    Zervimesine (CT1812) slowed lesion progression in geographic atrophy secondary to AMD in Phase 2 MAGNIFY trial results, offering a potential oral treatment option.

    UBX1325 Matches Aflibercept in Vision Gains for DME at 36 Weeks

    UBX1325 demonstrated noninferiority to aflibercept in visual acuity gains in patients with diabetic macular edema over 36 weeks in the Phase 2b ASPIRE study.

    Roflumilast Foam 0.3% for Scalp, Body Psoriasis Effective, Safe for Patients

    Roflumilast foam 0.3% achieved significant efficacy and rapid symptom control in scalp and body psoriasis, with an FDA decision expected by late May 2025.
    Más Menos
    4 m